Previous report also indicates that activated IRF3 can attenuate TGF-β/Smad signaling, thus preventing in vivo differentiation of iTreg in colons and epithelial-to-mesenchymal transition of tumor cells, independent of its potency as transcription factor20. This evidence concerns the gene TGFB1 and neoplasm.